

**Metro-Minnesota Community Oncology Research Consortium  
Ovarian Cancer Clinical Research Trials**

**Studies currently open to accrual:**

**NRG-GY007: Ruxolitinib with front-line neoadjuvant & post-surgical therapy (NCT# 02713386)**

- **Targeted Disease:** Stage III or IV ovarian Cancer
- **Treatment line:** untreated and plan to have chemotherapy with tumor reductive surgery
- Tests an oral JAK inhibitor (Ruxolitinib) with Paclitaxel and Carboplatin
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**NRG-GY005: Cediranib + Olaparib vs. Olaparib alone vs. Standard of Care (NCT# 02502266)**

- **Targeted Disease:** Platinum resistant recurrent cancer (recurred within 6 months of chemo)
- **Treatment line:** 2<sup>nd</sup> line or greater
- Tests how well a VEGF inhibitor Cediranib (Recentin) and a PARP inhibitor Olaparib (Lynparza) work when given together or separately
- **Principal Investigator:** Dr. Rachel Lerner

**NRG-CC004: Bupropion in improving sexual desire in women with GYN cancer (NCT# 03180294)**

- **Targeted Disease:** Any gynecologic or breast cancer
- **Treatment line:** Completed all surgery, chemo and/or radiation > 6 months ago
- Tests how well bupropion hydrochloride (Wellbutrin) works in improving sexual desire compared to placebo
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**(Monticello only) MNCCTN004: Nasal Vestibulitis Natural History Evaluation (Minnesota Cancer Clinical Trials Network: [www.cancer.umn.edu/mncctn](http://www.cancer.umn.edu/mncctn))**

- **Targeted Disease:** Any disease requiring chemotherapy
- **Treatment line:** First line
- Complete questionnaires at baseline, with each dose of chemotherapy and one month following chemotherapy to determine which chemo drugs are related to nasal symptoms
- **Principal Investigator:** Dr. Daniel Anderson

**GOG3020 ATHENA: Rucaparib + Nivolumab (NCT# 03522246)**

- **Targeted Disease:** Stage III or IV ovarian cancer
- **Treatment line:** After response to front line platinum-based chemotherapy
- Compares Rucaparib (Rubraca) PARP inhibitor or placebo + Nivolumab (Opdivo) immunotherapy or placebo as maintenance treatment
- **Principal Investigator:** Dr. Emily Prendergast

**Study details for NCT # at <https://clinicaltrials.gov/>**

**Contact MMCORC for more information at 952-993-1517 or [mmcorc.org](http://mmcorc.org)**



*Bringing the advantages of cancer research to the community*

**Metro-Minnesota Community Oncology Research Consortium  
Ovarian Cancer Clinical Research Trials**

**Studies pending and will open to accrual in the future:**

**(Upcoming) NRG-GY019: Letrozole with or without Paclitaxel and Carboplatin (NCT# 04095364)**

- **Targeted Disease:** Newly diagnosed Stage II-IV low-grade serous ovarian cancer
- **Treatment line:** following cytoreductive surgery
- Tests how well letrozole (enzyme inhibitor that lowers estrogen levels) works with or without paclitaxel/carboplatin
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**(Suspended) NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride with Atzeolizumab and/or Bevacizumab (NCT# 02839707)**

- **Targeted Disease:** platinum-resistant recurrent ovarian cancer (recurred within 6 months of chemo)
- **Treatment line:** 2<sup>nd</sup> line or greater
- Tests the addition of Atezolizumab immunotherapy to pegylated liposomal doxorubicin hydrochloride with or without Bevacizumab
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**(Suspended) ECOG-ACRIN EAE161: Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients with Ovarian Cancer receiving Bevacizumab (NCT# 03412630)**

- **Targeted Disease:** platinum-resistant recurrent or persistent epithelial ovarian cancer
- **Treatment line:** First line
- Tests how well computed tomography (CT) perfusion imaging works in predicting outcomes in patients receiving bevacizumab
- **Principal Investigator:** Dr. David King

**(Suspended) NRG-GY016: Pembrolizumab + Epacadostat (NCT# 03602586)**

- **Targeted Disease:** recurrent or persistent clear cell ovarian cancer
- **Treatment line:** 2<sup>nd</sup>, 3<sup>rd</sup>, or 4<sup>th</sup>
- Tests combination of Pembrolizumab (Keytruda) immunotherapy with Epacadostat (inhibitor of enzymes needed for cell growth)
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**(Suspended) NRG-GY014: Tazemetostat (NCT# 03348631)**

- **Targeted Disease:** platinum-resistant recurrent or persistent ovarian endometrioid or clear cell cancer
- **Treatment line:** 2<sup>nd</sup>, 3<sup>rd</sup>, or 4<sup>th</sup>
- Tests how well Tazemetostat (works to stop growth of tumor cells)
- **Principal Investigator:** Dr. Jessica Thomes Pepin

**Study details for NCT # at <https://clinicaltrials.gov/>**

**Contact MMCORC for more information at 952-993-1517 or [mmcorc.org](http://mmcorc.org)**



*Bringing the advantages of cancer research to the community*